Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Phenylboronic Acid | HCID 66827 | — |
| Reactant | Oxalate | HCID 71081 | — |
| Reactant | 2-[(3-Iodophenyl)(1-methylpiperidin-4-yloxy)methyl]benzothiazole | HCID 56947458 | — |
| Catalyst | palladium(II) acetate | HCID 167845 | — |
| Catalyst | 1,1`-Bis(diphenylphosphino)ferrocene | HCID 15241612 | — |
| Solvent | Acetone | HCID 180 | — |
| Product | Oxalate | HCID 71081 | — |
| Product | 2-[Biphenyl-3-yl(1-methylpiperidin-4-yloxy)methyl]benzothiazole | HCID 66835997 | — |
Reaction Steps
A mixture of 2-[(3-iodophenyl)(1-methylpiperidin-4-yloxy)methyl]benzothiazole (200 mg), phenylboronic acid (70 mg), palladium acetate (4.8 mg) and 1,1-bis(diphenylphosphino)ferrocene is placed in a round-bottom flask and purged with argon. A 1M aqueous degassed solution of potassium carbonate (1.51 mL) and degassed tetrahydrofuran (2 mL) are introduced. The mixture is heated at 95° C. for 30 min, cooled back to room temperature and filtered over a celite pad. The cake is rinsed with ethyl acetate and water. The pooled phases are decanted. The organic phase is dried over magnesium sulfate and concentrated. The residue is purified by column chromatography (gradient dichloromethane/methanol from 98/2 to 90/10) to give the crude base which is then converted to the oxalate in acetone to give 2-[biphenyl-3-yl(1-methylpiperidin-4-yloxy)methyl]benzothiazole, oxalate as a beige amorphous solid.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US09029357B2 |
|---|
| Source dataset | uspto-grants-2015_05 |
|---|
| ORD ID | ord-e5341bf0124d43ddaaa765fcaf8ac944 |
|---|
| Source note | uspto-grants-2015_05 |
|---|